In vivo anti-tumor activity of tumor-targeting pH-sensitive lipoprotein-mimic nanocarrier with paclitaxel loaded.
10.19540/j.cnki.cjcmm.20181221.008
- Author:
Cong-Hui CHEN
1
;
Meng-Yu LIU
1
Author Information
1. School of Pharmaceutical Science,Linyi University Linyi 276000,China.
- Publication Type:Journal Article
- Keywords:
in-vivo antitumor activity;
lipoprotein-mimic nanocarrier;
pH-sensitivity;
paclitaxel;
tumor-targeting
- MeSH:
Animals;
Antineoplastic Agents, Phytogenic;
pharmacology;
Cell Line, Tumor;
Drug Carriers;
Hydrogen-Ion Concentration;
Lipoproteins;
Mice;
Mice, Nude;
Nanoparticles;
Neoplasms, Experimental;
drug therapy;
Paclitaxel;
pharmacology
- From:
China Journal of Chinese Materia Medica
2019;44(10):2072-2077
- CountryChina
- Language:Chinese
-
Abstract:
Paclitaxel( PTX) is used as a broad spectrum anti-tumor medicine. However,serious drawbacks restrict clinical application of PTX. In this study,we prepared tumor-targeting and pH-sensitive lipoprotein-mimic nanocarrier containing paclitaxel( BSALC/DOPE-PTX) to study the effective antitumor activity. The in vivo targeting ability of the nanocarrier in tumor bearing nude mice was evaluated by using a Kodak in vivo imaging system FX PRO. The in vivo anti-tumor activity was evaluated in MDA-MB-231 tumor bearing mice,and representative sections were stained with hematoxylin and eosin( H&E),and examined by light microscopy. The results showed that DiR-loaded FA-BSA-LC/DOPE selectively targeted tumor,and had a relatively long residence in the tumor tissue. According to the in vivo anti-tumor activity study,FA-BSA-LC/DOPE-PTX exhibited an outstanding tumor inhibition effect with a tumor growth inhibition rate of 79.3%,and tumor tissue sections stained by hematoxylin and eosin( HE) showed severe necrosis areas and many dead cells with condensed nuclei in the FA-BSA-LC/DOPE-PTX group. Therefore,FA-BSA-LC/DOPE-PTX is a biocompatible,tumor-targeting and pH-sensitive lipoprotein-mimic nanocarrier,with a very marked anti-tumor activity in tumor-bearing mice in vivo.
